Details of the Drug

General Information of Drug (ID: DMT6AM2)

Drug Name

Ozanimod

Synonyms

1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
Ulcerative colitis	DD71	Phase 3	[3]
Crohn disease	DD70	Phase 2	[3]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

404.5

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 4.46 mcgh/L [4]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.244 mcg/L [4]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 6-8 h [4]
Clearance: The apparent oral clearance of drug is 192 L/h [4]
Elimination: After a 0.92 mg dose of radiolabeled ozanimod was administered, about 26% of the labeled drug was accounted for in the urine and 37 % in the feces, mainly in the form of inactive metabolites [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 17 - 21 hours [5]
Metabolism: The drug is metabolized via the ALDH/ADH, NAT-2, Monoamine Oxidase B, and AKR 1C1/1C2 [4]
Vd: The volume of distribution (Vd) of drug is 5590 L [4]

Chemical Identifiers

Formula: C23H24N4O3
IUPAC Name: 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
Canonical SMILES: CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N
InChI: InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
InChIKey: XRVDGNKRPOAQTN-FQEVSTJZSA-N

Cross-matching ID

PubChem CID: 52938427
CAS Number: 1306760-87-1
DrugBank ID: DB12612
TTD ID: D07EDB
ACDINA ID: D01311

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ozanimod (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Ivosidenib.	Acute myeloid leukaemia [2A60]	[13]
Oliceridine	DM6MDCF	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Oliceridine.	Acute pain [MG31]	[13]
Levalbuterol	DM5YBO1	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Levalbuterol.	Asthma [CA23]	[13]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Ozanimod due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[14]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ozanimod and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[15]
Lisocabtagene maraleucel	DMP45ME	Major	Additive immunosuppressive effects by the combination of Ozanimod and Lisocabtagene maraleucel.	Diffuse large B-cell lymphoma [2A81]	[16]
Axicabtagene ciloleucel	DMYHN59	Major	Additive immunosuppressive effects by the combination of Ozanimod and Axicabtagene ciloleucel.	Diffuse large B-cell lymphoma [2A81]	[16]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Ozanimod caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[14]
Avapritinib	DMK2GZX	Major	Additive immunosuppressive effects by the combination of Ozanimod and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[16]
177Lu-DOTATATE	DMT8GVU	Major	Additive immunosuppressive effects by the combination of Ozanimod and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[16]
Lurbinectedin	DMEFRTZ	Major	Additive immunosuppressive effects by the combination of Ozanimod and Lurbinectedin.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Selpercatinib.	Lung cancer [2C25]	[13]
Tisagenlecleucel	DMM9BJD	Major	Additive immunosuppressive effects by the combination of Ozanimod and Tisagenlecleucel.	Mature B-cell lymphoma [2A85]	[16]
Belantamab mafodotin	DMBT3AI	Major	Additive immunosuppressive effects by the combination of Ozanimod and Belantamab mafodotin.	Multiple myeloma [2A83]	[16]
Macimorelin	DMQYJIR	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[13]
Lefamulin	DME6G97	Major	Increased risk of ventricular arrhythmias by the combination of Ozanimod and Lefamulin.	Pneumonia [CA40]	[13]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Ozanimod due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[17]
Tildrakizumab	DMLW9HG	Major	Additive immunosuppressive effects by the combination of Ozanimod and Tildrakizumab.	Psoriasis [EA90]	[16]
Risankizumab	DMM32GT	Major	Additive immunosuppressive effects by the combination of Ozanimod and Risankizumab.	Psoriasis [EA90]	[16]
Upadacitinib	DM32B5U	Major	Additive immunosuppressive effects by the combination of Ozanimod and Upadacitinib.	Rheumatoid arthritis [FA20]	[16]
-----------


⏷ Show the Full List of 20 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric oxide black	E00522	16211978	Colorant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ozanimod 0.23 mg capsule	0.23 mg	Capsule	Oral
Ozanimod 0.46 mg capsule	0.46 mg	Capsule	Oral
Ozanimod 0.92 mg capsule	0.92 mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT02294058) Phase 3 Study of RPC1063 in Relapsing MS. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	FDA Approved Products: Zeposia (Ozanimod) oral capsules
5	Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
9	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
10	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
11	Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
12	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
13	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
14	Cerner Multum, Inc. "Australian Product Information.".
15	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.